Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Allergen-specific antibodies are immunoglobulins targeting distinct allergenic proteins. IgE is central in mediating allergic reactions through binding to high-affinity Fc receptors on mast cells and basophils, leading to cell activation and histamine release upon allergen exposure[1][3][7]. Allergen-specific IgG, particularly IgG4, may develop after allergen immunotherapy and can block IgE-allergen interaction, ameliorating symptoms and promoting immune tolerance[3][6][8]. Allergen-specific antibodies are used as diagnostic biomarkers, guides for immunotherapy, and as direct therapeutic targets, with anti-IgE monoclonal antibodies showing efficacy in conditions like asthma, urticaria, and food allergy[4][8].
Blocking IgE binding to receptors on mast cells and basophils (anti-IgE) Blocking allergen binding to IgE (blocking IgG) Disrupting IgE-facilitated antigen presentation (blocking antibody)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Allergen-specific antibody.